These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 32763546)
1. Meta-analysis of randomized controlled trials of galantamine in schizophrenia: significant cognitive enhancement. Koola MM; Looney SW; Hong H; Pillai A; Hou W Psychiatry Res; 2020 Sep; 291():113285. PubMed ID: 32763546 [TBL] [Abstract][Full Text] [Related]
2. Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement. Koola MM Prim Care Companion CNS Disord; 2018 Mar; 20(2):. PubMed ID: 29570959 [TBL] [Abstract][Full Text] [Related]
3. A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia. Buchanan RW; Kelly DL; Weiner E; Gold JM; Strauss GP; Koola MM; McMahon RP; Carpenter WT J Clin Psychopharmacol; 2017 Aug; 37(4):394-400. PubMed ID: 28590362 [TBL] [Abstract][Full Text] [Related]
4. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Koola MM; Buchanan RW; Pillai A; Aitchison KJ; Weinberger DR; Aaronson ST; Dickerson FB Schizophr Res; 2014 Aug; 157(1-3):84-9. PubMed ID: 24878431 [TBL] [Abstract][Full Text] [Related]
5. Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia. Koola MM Mol Neuropsychiatry; 2018 Dec; 4(3):134-148. PubMed ID: 30643787 [TBL] [Abstract][Full Text] [Related]
6. Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond. Koola MM Psychiatry Res; 2020 Nov; 293():113409. PubMed ID: 32829072 [TBL] [Abstract][Full Text] [Related]
7. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Lindenmayer JP; Khan A Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275 [TBL] [Abstract][Full Text] [Related]
8. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis. Kishi T; Ikuta T; Oya K; Matsunaga S; Matsuda Y; Iwata N Int J Neuropsychopharmacol; 2018 Aug; 21(8):748-757. PubMed ID: 29762677 [TBL] [Abstract][Full Text] [Related]
9. The effects of galantamine on psychopathology in chronic stable schizophrenia. Conley RR; Boggs DL; Kelly DL; McMahon RP; Dickinson D; Feldman S; Ball MP; Buchanan RW Clin Neuropharmacol; 2009; 32(2):69-74. PubMed ID: 18978489 [TBL] [Abstract][Full Text] [Related]
10. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine. Koola MM Schizophr Res Cogn; 2016 Jun; 4():4-9. PubMed ID: 27069875 [TBL] [Abstract][Full Text] [Related]
12. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678 [TBL] [Abstract][Full Text] [Related]
15. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Lee SW; Lee JG; Lee BJ; Kim YH Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705 [TBL] [Abstract][Full Text] [Related]
16. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Dyer MA; Freudenreich O; Culhane MA; Pachas GN; Deckersbach T; Murphy E; Goff DC; Evins AE Schizophr Res; 2008 Jul; 102(1-3):88-95. PubMed ID: 18325740 [TBL] [Abstract][Full Text] [Related]
17. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Kelly DL; McMahon RP; Weiner E; Boggs DL; Dickinson D; Conley RR; Buchanan RW Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339 [TBL] [Abstract][Full Text] [Related]
18. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity. Koola MM; Nikiforuk A; Pillai A; Parsaik AK J Geriatr Care Res; 2018; 5(2):57-67. PubMed ID: 30984874 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Rosse RB; Deutsch SI Clin Neuropharmacol; 2002; 25(5):272-5. PubMed ID: 12410061 [TBL] [Abstract][Full Text] [Related]
20. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Albuquerque EX; Santos MD; Alkondon M; Pereira EF; Maelicke A Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S19-25. PubMed ID: 11669505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]